JP2008532516A5 - - Google Patents

Download PDF

Info

Publication number
JP2008532516A5
JP2008532516A5 JP2008500763A JP2008500763A JP2008532516A5 JP 2008532516 A5 JP2008532516 A5 JP 2008532516A5 JP 2008500763 A JP2008500763 A JP 2008500763A JP 2008500763 A JP2008500763 A JP 2008500763A JP 2008532516 A5 JP2008532516 A5 JP 2008532516A5
Authority
JP
Japan
Prior art keywords
increased
reduced
cells
average
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008500763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007353 external-priority patent/WO2006098887A2/en
Publication of JP2008532516A publication Critical patent/JP2008532516A/ja
Publication of JP2008532516A5 publication Critical patent/JP2008532516A5/ja
Pending legal-status Critical Current

Links

JP2008500763A 2005-03-11 2006-02-27 遺伝子破壊、組成物、およびそれに関連する方法 Pending JP2008532516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66117305P 2005-03-11 2005-03-11
US74052205P 2005-11-29 2005-11-29
PCT/US2006/007353 WO2006098887A2 (en) 2005-03-11 2006-02-27 Gene disruptions, compositions and methods relating thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009049942A Division JP2009168820A (ja) 2005-03-11 2009-03-03 遺伝子破壊、組成物、およびそれに関連する方法

Publications (2)

Publication Number Publication Date
JP2008532516A JP2008532516A (ja) 2008-08-21
JP2008532516A5 true JP2008532516A5 (cg-RX-API-DMAC10.html) 2009-04-23

Family

ID=36992194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500763A Pending JP2008532516A (ja) 2005-03-11 2006-02-27 遺伝子破壊、組成物、およびそれに関連する方法
JP2009049942A Pending JP2009168820A (ja) 2005-03-11 2009-03-03 遺伝子破壊、組成物、およびそれに関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009049942A Pending JP2009168820A (ja) 2005-03-11 2009-03-03 遺伝子破壊、組成物、およびそれに関連する方法

Country Status (6)

Country Link
US (1) US20110097330A1 (cg-RX-API-DMAC10.html)
EP (1) EP1863340A2 (cg-RX-API-DMAC10.html)
JP (2) JP2008532516A (cg-RX-API-DMAC10.html)
AU (1) AU2006223579A1 (cg-RX-API-DMAC10.html)
CA (1) CA2601677A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006098887A2 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
PL1781682T3 (pl) 2004-06-24 2013-08-30 Mayo Found Medical Education & Res Polipeptyd kostymulujący B7-H5
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US8231872B2 (en) * 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
US8609816B2 (en) 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
JP2010515428A (ja) * 2006-11-14 2010-05-13 ジェネンテック， インコーポレイテッド 新規の遺伝子破壊、組成物、およびそれに関連する方法
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc SYSTEMS AND METHOD FOR PROCESSING, TRANSMITTING AND DISPLAYING SENSOR DATA
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
CN104039357A (zh) * 2011-06-10 2014-09-10 哈佛学院校长同事会 胰腺β-细胞增殖的调节
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
CN111803465B (zh) 2013-03-15 2023-05-09 阿根塔创新有限公司 可咀嚼配制物
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2017136712A1 (en) * 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2020518915A (ja) 2017-04-27 2020-06-25 パスハラキス スタブロスＰＡＳＣＨＡＬＡＫＩＳ， Ｓｔａｖｒｏｓ 自動眼底画像分析用のシステムおよび方法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2020274805A1 (en) * 2019-05-10 2021-10-28 Ketoswiss Ag Ketone bodies enclosed in microbeads
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003518361A (ja) * 1998-09-01 2003-06-10 ジェネンテック・インコーポレーテッド 更なるｐｒｏポリペプチドとその配列
JP2003531811A (ja) * 1999-03-08 2003-10-28 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002217989A1 (en) * 2000-11-15 2002-05-27 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
WO2002045495A2 (en) * 2000-12-06 2002-06-13 Deltagen, Inc. Transgenic mice containing targeted gene disruptions

Similar Documents

Publication Publication Date Title
Lundberg et al. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPα-interaction
Kruger et al. Stereochemical control yields mucin mimetic polymers
ES2655591T3 (es) Métodos para la regulación de células madre
ES2379413T3 (es) Procedimientos para detectar la enfermedad inflamatoria del intestino
KR20240116566A (ko) 노화 세포 치료를 위한 단백질 치료제
JP2009168820A (ja) 遺伝子破壊、組成物、およびそれに関連する方法
DE60128701T2 (de) Claudin polypeptide
Chrobak et al. CD73 plays a protective role in collagen-induced arthritis
WO2012061537A9 (en) Methods for treating hair loss disorders
JP2003524387A (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
CA2298540A1 (en) Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
US20030143579A1 (en) Inhibitors of apoptosis
Bonaventura et al. Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis
JP2002503451A (ja) カプサイシン受容体をコードする核酸配列
JP6890835B2 (ja) 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
US20110020380A1 (en) Human Tumor Necrosis Factor TR18 and Methods Based Thereon
DE69931284T9 (de) Menschliches Neurotrimin-Homolog
Singh et al. Functional roles of osteoactivin in normal and disease processes
JP2005511012A (ja) ヒトｃＤＮＡおよびタンパク質およびその使用
Yang et al. Quadruped gait and regulation of apoptotic factors in Tibiofemoral joints following intra-articular rhPRG4 injection in Prg4 null mice
ES2262819T3 (es) Ligando natural para el receptor gpr86 acoplado a proteinas g huerfano y metodos de uso.
EP1756270A2 (en) Diagnosis and treatment of myeloid and lymphoid cell cancers
US20170360888A1 (en) Methods for treating inflammatory arthritis
Yang et al. Structural insight for roles of DR5 death domain mutations on oligomerization of DR5 death domain–FADD complex in the death-inducing signaling complex formation: a computational study
US10485849B2 (en) Syndecan peptides and polypeptides as inhibitors of vascular endothelial growth factor receptor-2 (VEGFR2) and very late antigen-4 (VLA-4)